New drug access for Hard-to-Treat blood cancer patients
NCT ID NCT05269771
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program offers ruxolitinib (Jakavi) to people aged 12 and older with polycythemia vera, a blood cancer that causes too many red blood cells. It is for patients whose disease has not responded to or who cannot take standard treatments like hydroxyurea. Participants take daily tablets at home under their doctor's guidance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib (also known as Jakavi)
What this could lead to
If successful, this program could provide a treatment option for polycythemia vera patients who have not responded to or cannot tolerate standard therapies.
What could go wrong
This is an access program, not a formal trial, so it does not test whether ruxolitinib works better than other options. Results may not apply to all patients, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Orange, New South Wales, 2800, Australia
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Calgary, Alberta, T2N 2T9, Canada
-
Novartis Investigative Site
Tehran, 11367, Iran
-
Novartis Investigative Site
Kfar Saba, Israel, 44281, Israel
-
Novartis Investigative Site
Kfar Saba, 44281, Israel
-
Novartis Investigative Site
Rehovot, 7610001, Israel
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Tel Giborim Holon, 58100, Israel
-
Novartis Investigative Site
Groningen, 9700RB, Netherlands
-
Novartis Investigative Site
Gdansk, 80-214, Poland
-
Novartis Investigative Site
Katowice, 40-027, Poland
-
Novartis Investigative Site
Krakow, 31-501, Poland
-
Novartis Investigative Site
Warsaw, 00-791, Poland
-
Novartis Investigative Site
Warsaw, 04-141, Poland
-
Novartis Investigative Site
Wałbrzych, 58-309, Poland
-
Novartis Investigative Site
Wroclaw, 50-367, Poland
-
Novartis Investigative Site
Hereford, HR1 2ER, United Kingdom
-
Novartis Investigative Site
Kent, CT9 4AN, United Kingdom
-
Novartis Investigative Site
London, NW3 2PF, United Kingdom
-
Novartis Investigative Site
London, SE5 8AD, United Kingdom
-
Novartis Investigative Site
London, WC1E 6HX, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 7LJ, United Kingdom
-
Novartis Investigative Site
Poole, BH15 2JB, United Kingdom
-
Novartis Investigative Site
Salisbury, SP2 8BJ, United Kingdom